LEADER 04816oam 2200481 450 001 9910583388103321 005 20190911100031.0 010 $a0-12-802052-0 010 $a0-12-802025-3 035 $a(OCoLC)956735866 035 $a(MiFhGG)GVRL9JUC 035 $a(EXLCZ)993710000000673708 100 $a20160810h20162016 uy 0 101 0 $aeng 135 $aurun|---uuuua 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aClinical challenges in therapeutic drug monitoring $especial populations, physiological conditions, and pharmacogenomics /$fedited by William Clarke, PhD, MBA, Associate Professor of Pathology, Johns Hopkins University, Baltimore, MD, Amitava Dasgupta, Professor of Pathology and Laboratory Medicine, University of Texas Medical School at Houston, Houston, TX 210 1$aAmsterdam :$cElsevier,$d[2016] 210 4$d?2016 215 $a1 online resource (xvi, 360 pages) $cillustrations (some color) 225 0 $aGale eBooks 300 $aDescription based upon print version of record. 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aFront Cover; Clinical Challenges in Therapeutic Drug Monitoring; Copyright Page; Contents; List of Contributors; Preface; 1 Overview of Therapeutic Drug Monitoring; 1.1 Introduction; 1.2 Principles of TDM; 1.3 Clinical Areas in Which TDM is Routine Practice; 1.3.1 Epilepsy; 1.3.2 Organ Transplantation; 1.3.3 Cardiology (Antiarrhythmic Drugs); 1.3.4 Psychiatry; 1.3.5 Infectious Disease; 1.3.6 Oncology; 1.4 Conclusions; References; 2 Immunoassays and Issues With Interference in Therapeutic Drug Monitoring; 2.1 Introduction; 2.2 Immunoassay Platforms Used in TDM 327 $a2.3 Interference of Bilirubin, Hemolysis, and Lipemia2.4 Interferences in Digoxin Immunoassays; 2.4.1 DLIS Interferences in Digoxin Immunoassays; 2.4.2 Effect of Digibind and DigiFab on Digoxin Immunoassays; 2.4.3 Potassium-Sparing Diuretics and Digoxin Immunoassays; 2.4.4 Herbal Supplements and Digoxin Immunoassays; 2.5 Issues of Interferences With Immunoassays for Immunosuppressants; 2.5.1 Metabolite Interferences in Cyclosporine Immunoassays; 2.5.2 Metabolite Interferences in Tacrolimus Immunoassays; 2.5.3 Metabolite Interferences in Sirolimus and Everolimus Immunoassays 327 $a2.5.4 Metabolite Interferences in Mycophenolic Acid Immunoassays2.6 Interferences in Immunoassays for Anticonvulsants; 2.6.1 Interferences in Phenytoin Immunoassays; 2.6.2 Interferences in Carbamazepine Immunoassays; 2.6.3 Interferences in Phenobarbital and Valproic Acid Immunoassays; 2.6.4 Interferences in Immunoassays for Newer Anticonvulsants; 2.7 Interferences in Immunoassays for TCAs; 2.7.1 Interference of Phenothiazines and Their Metabolites in Immunoassays for TCAs; 2.7.2 Interference of Carbamazepine in Immunoassays for TCAs 327 $a2.7.3 Interference of Cyproheptadine and Quetiapine With Immunoassays for TCAs2.7.4 Interference of Miscellaneous Drugs With Immunoassays for TCAs; 2.8 Conclusions; References; 3 Application of Chromatography Combined With Mass Spectrometry in Therapeutic Drug Monitoring; 3.1 Introduction; 3.2 Liquid Chromatography; 3.3 Mass Spectrometry; 3.3.1 Ion Source; 3.3.2 Mass Analyzers; 3.3.2.1 Quadrupole Analyzers; 3.3.2.2 Ion Trap Analyzers; 3.3.2.3 TOF Analyzers; 3.3.3 Detectors; 3.4 Preanalytical Stage; 3.5 Application of LC-MS/MS Methods in TDM; 3.5.1 Immunosuppressants; 3.5.2 Anticonvulsants 327 $a3.5.3 Antidepressants3.5.4 Antifungal Drugs; 3.5.5 Others Drug Classes; 3.6 LC-MS/MS Limitations; 3.7 Conclusions; References; 4 Monitoring Free Drug Concentration: Clinical Usefulness and Analytical Challenges; 4.1 Introduction; 4.2 Drug-Protein Binding; 4.3 Drugs Requiring Free Drug Monitoring; 4.4 Conditions in Which Monitoring Free Anticonvulsants is Necessary; 4.4.1 Clinical Utility of Monitoring Free Phenytoin Concentrations; 4.4.2 Clinical Utility of Monitoring Free Valproic Acid Concentration; 4.4.3 Clinical Utility of Monitoring Free Carbamazepine Concentrations 327 $a4.5 Mechanisms of Elevated Free Anticonvulsant Levels in Various Pathophysiological Conditions 330 $aThis guide surveys critical issues in therapeutic drug monitoring for non-toxicologists who want to gain greater insight into the unique requirements of special populations and learn how to avoid drug toxicity within a narrow therapeutic window. 606 $aDrug monitoring 615 0$aDrug monitoring. 676 $a615.7 702 $aClarke$b William 702 $aDasgupta$b Amitava$f1958- 801 0$bMiFhGG 801 1$bMiFhGG 906 $aBOOK 912 $a9910583388103321 996 $aClinical challenges in therapeutic drug monitoring$91946724 997 $aUNINA